Quantinno Capital Management LP Has $928,000 Position in Grifols, S.A. (NASDAQ:GRFS)

Quantinno Capital Management LP lifted its stake in Grifols, S.A. (NASDAQ:GRFS) by 11.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 104,545 shares of the biotechnology company’s stock after buying an additional 10,830 shares during the period. Quantinno Capital Management LP’s holdings in Grifols were worth $928,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in Grifols by 49.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 1,135 shares during the period. Signaturefd LLC boosted its position in shares of Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 2,153 shares in the last quarter. AQR Capital Management LLC bought a new stake in Grifols in the second quarter valued at about $89,000. HighTower Advisors LLC raised its position in Grifols by 12.5% in the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 1,546 shares in the last quarter. Finally, Cetera Advisors LLC acquired a new position in Grifols in the first quarter worth about $147,000.

Analyst Ratings Changes

Separately, Berenberg Bank raised Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Price Performance

Shares of NASDAQ:GRFS opened at $7.33 on Friday. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The business’s fifty day moving average price is $8.46 and its two-hundred day moving average price is $8.09. Grifols, S.A. has a fifty-two week low of $5.30 and a fifty-two week high of $12.15.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.